SGLT-2I may be preferred over DPP-4I for frail patients with T2D (of 11) Pediatric News , 31 Aug 2022 Key clinical point: Sodium-glucose cotransporter-2 inhibitors (SGLT-2I) offered advantages over dipeptidyl peptidase-4…